
Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO
2026-11-01 10:10:33Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 31 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with the latest insights into its performance and outlook.
Read More
Ajanta Pharma Ltd. Rallies 5.14% and Approaches 50 DMA Resistance — A Key Technical Test Ahead
2026-10-26 15:47:24The Sensex advanced 0.66% on 26 Oct 2026, yet Ajanta Pharma Ltd. outperformed sharply with a 5.14% gain, touching an intraday high of Rs 3,450. This 3.96 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.
Read More
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
2026-10-21 10:10:38Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Ajanta Pharma Ltd. is Rated Hold
2026-10-10 10:10:35Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 10 October 2026.
Read More
Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals
2026-10-05 08:00:53Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish trend. Despite a day-on-day price decline of 0.97%, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions.
Read MoreAjanta Pharma Gains 0.94%: 3 Key Technical and Valuation Factors Driving the Week
2026-10-04 14:00:31Key Events This Week 28 Sep: Stock opens at Rs.3,530.60 amid downgrade to Hold 29 Sep: Downgrade to Hold announced; technical momentum shifts mildly bearish 30 Sep: Stock rallies 1.67% on improving technical signals 1 Oct: Technical momentum upgrades to bullish; stock closes at Rs.3,617.45 2 Oct: No trading data available; week closes at Rs.3,582.20 (+0.94%) Week Open<div class="st...
Read More
Ajanta Pharma Ltd. Technical Momentum Shifts Signal Bullish Outlook Amid Market Volatility
2026-10-01 08:00:37Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a blend of technical indicator signals and robust price action, positioning the stock favourably against broader market benchmarks such as the Sensex.
Read More
Ajanta Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals
2026-09-29 08:14:18Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 28 Sep 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate strong financial performance and market-beating returns, evolving technical indicators and valuation concerns have tempered investor enthusiasm.
Read More
Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals
2026-09-29 08:00:57Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in its share price, the stock continues to outperform the broader market, reflecting a complex interplay of technical indicators that investors should carefully analyse.
Read MoreDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
18-Nov-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 18 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
17-Nov-2026 | Source : BSEThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 16 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
09-Nov-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 09 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Corporate Actions
No Upcoming Board Meetings
Ajanta Pharma Ltd. has declared 1600% dividend, ex-date: 05 Aug 26
Ajanta Pharma Ltd. has announced 2:5 stock split, ex-date: 20 Mar 15
Ajanta Pharma Ltd. has announced 1:2 bonus issue, ex-date: 22 Jun 22
No Rights history available